Our physicians remain committed to participating in ongoing retina research, providing our patients with access to promising new treatments through clinical trials. In fact, our research program has grown to become one of the largest in the country for a community-based practice and rivals those of some of the biggest academic medical centers.

We recently opened four new clinical trials:

Diabetic Macular Edema
DRCR Protocol AN (Lubbock) — A Phase II evaluation of tonabersat for diabetic macular edema.

Intravitreal Injection Device
COOL3s (Dallas Main) — A controlled trial studying the use of rapid cooling anesthesia as local anesthesia for patients receiving intravitreal injections.

OPTYK-1 (Plano) — A study to evaluate the efficacy and safety of ESK-001 in patients with active noninfectious intermediate, posterior or panuveitis.

Wet Age-related Macular Degeneration (AMD)
Odyssey (Dallas Main, Arlington, Plano) — A Phase IIb study of suprachoroidally administered CLS-AX in participants with neovascular age-related macular degeneration (AMD).

Click here to view all our current, actively enrolling clinical trials.

For more information or to determine your eligibility for any of these studies, please contact our research department at (214) 692-6885, ext. 1.